Showing results (131-140 of 365) with videos related to
Sort By:
Pageof 37
Current Therapeutic Research, Clinical and Experimental|April 1, 2014
Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter studySung-Bae Kim, Jung Shin Lee, Heung Tae Kim, et al.Psycho-Oncology|March 26, 2014
Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patientsEun Kyung Choi, Im-Ryung Kim, Oliver Chang, et al.Breast (Edinburgh, Scotland)|March 3, 2015
Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in KoreaYeon Hee Park, Su Jin Lee, Hyun Ae Jung, et al.Future Oncology (London, England)|March 19, 2025
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugatesYeon Hee Park, Giampaolo Bianchini, Javier Cortés, et al.Breast Cancer Research and Treatment|August 14, 2019
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, et al.Journal of Cancer Research and Clinical Oncology|June 1, 2011
Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancySoohyeon Lee, Youngwook Kim, Jong-Mu Sun, et al.Cancers|November 13, 2021
Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant ChemotherapyHae Hyun Jung, Ji-Yeon Kim, Eun Yoon Cho, et al.Scientific Reports|May 31, 2020
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysisSeock-Ah Im, Binghe Xu, Wei Li, et al.Molecular Cancer Therapeutics|July 7, 2023
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation StudyFunda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, et al.Breast Cancer Research and Treatment|September 6, 2021
Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in KoreaYeon Hee Park, Vassiliki Karantza, Shawna R Calhoun, et al.Pageof 37